RecallHawk

DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ (HUMAN RECOMBINANT))

JANSSEN BIOTECH

Summary

FDA approved DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ (HUMAN RECOMBINANT)) by JANSSEN BIOTECH. BLA (Biologic) approval (Labeling) on 2026-02-12. INJECTABLE, INJECTION.

Details

Source

Drug Approval

External ID

BLA761145-39

Action Date

2026-02-12

Status

Approved

Category

drug

Product Code

BLA (Biologic)

Product Description

DARZALEX FASPRO (generic: DARATUMUMAB AND HYALURONIDASE-FIHJ (HUMAN RECOMBINANT)), INJECTABLE, INJECTION. Application: BLA761145

Context & Analysis

JANSSEN BIOTECH has 5 FDA actions in our database.

Frequently Asked Questions

How often does JANSSEN BIOTECH have FDA actions?

JANSSEN BIOTECH has 5 FDA actions in our database, including 0 recalls and 0 device clearances.

Where can I find the official FDA record?

The official record is available on FDA.gov. Search for "BLA761145-39" on FDA.gov for the full record. You can also use the openFDA API to query this record programmatically.

Want to know the moment something like this happens?

Get alerts for drug

Related Actions